albiglutide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| glucagon-like peptide (GLP) analogues and agonists | 4927 | 782500-75-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, with antihyperglycemic activity. Albiglutide is composed of a GLP-1 (7-36) dimer fused to recombinant human albumin. Upon subcutaneous administration, this agent has a half-life of 4-7 days and resists degradation by dipeptidyl peptidase-4 (DPP-4).
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 5.70 | mg | P |
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| April 15, 2014 | FDA | GLAXOSMITHKLINE LLC |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Device use error | 325.71 | 53.06 | 52 | 376 | 5709 | 63482885 |
| Device leakage | 60.11 | 53.06 | 13 | 415 | 7083 | 63481511 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Device use error | 215.26 | 57.22 | 34 | 311 | 2341 | 34954245 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Device use error | 288.37 | 49.33 | 50 | 622 | 7051 | 79736665 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A10BJ04 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Glucagon-like peptide-1 (GLP-1) analogues |
| FDA MoA | N0000020058 | Glucagon-like Peptide-1 (GLP-1) Agonists |
| FDA EPC | N0000178480 | GLP-1 Receptor Agonist |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Diabetes mellitus type 2 | indication | 44054006 | DOID:9352 |
| Multiple endocrine neoplasia, type 2 | contraindication | 61808009 | |
| Medullary thyroid carcinoma | contraindication | 255032005 | DOID:3973 |
| History of medullary carcinoma of thyroid | contraindication | 429016002 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.01 | acidic |
| pKa2 | 3.31 | acidic |
| pKa3 | 3.82 | acidic |
| pKa4 | 4.11 | acidic |
| pKa5 | 4.44 | acidic |
| pKa6 | 9.65 | acidic |
| pKa7 | 11.88 | acidic |
| pKa8 | 12.25 | acidic |
| pKa9 | 12.57 | acidic |
| pKa10 | 12.65 | acidic |
| pKa11 | 12.88 | acidic |
| pKa12 | 12.95 | acidic |
| pKa13 | 13.05 | acidic |
| pKa14 | 13.2 | acidic |
| pKa15 | 13.23 | acidic |
| pKa16 | 13.38 | acidic |
| pKa17 | 13.39 | acidic |
| pKa18 | 13.55 | acidic |
| pKa19 | 13.56 | acidic |
| pKa20 | 13.67 | acidic |
| pKa21 | 13.75 | acidic |
| pKa22 | 13.8 | acidic |
| pKa23 | 13.91 | acidic |
| pKa24 | 12.18 | Basic |
| pKa25 | 11.11 | Basic |
| pKa26 | 10.51 | Basic |
| pKa27 | 7.86 | Basic |
| pKa28 | 5.98 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Glucagon-like peptide 1 receptor | GPCR | AGONIST | EC50 | 9.70 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
| Glucagon-like peptide 1 receptor | GPCR | AGONIST | EC50 | 7.70 | IUPHAR |
External reference:
| ID | Source |
|---|---|
| D08843 | KEGG_DRUG |
| 4033416 | VUID |
| N0000190764 | NUI |
| 4033416 | VANDF |
| CHEBI:78425 | CHEBI |
| CHEMBL2107841 | ChEMBL_ID |
| C534611 | MESH_SUPPLEMENTAL_RECORD_UI |
| 7386 | IUPHAR_LIGAND_ID |
| DB09043 | DRUGBANK_ID |
| 1534763 | RXNORM |
| 216723 | MMSL |
| 30258 | MMSL |
| d08251 | MMSL |
| 015507 | NDDF |
| 703129009 | SNOMEDCT_US |
| 703905003 | SNOMEDCT_US |
| C2607479 | UMLSCUI |
| 8829 | INN_ID |
| 145994868 | PUBCHEM_CID |
| 5E7U48495E | UNII |
Pharmaceutical products:
None